Voriconazole-associated severe hyponatremia

Medical Mycology

Volumn 50, Issue 1, 2012, Pages 103-105

  Kim, Kye Hyung ^a,b   Lee, Seunghwan ^a   Lee, Shinwon ^a,c   Yun, Na Ra ^a,d   Kim, Nam Joong ^a   Yu, Kyung Sang ^a   Jang, In Jin ^a   Park, Wan Beom ^a   Oh, Myoung Don ^a  

^a Seoul National University College of Medicine   (South Korea)

^b Pusan National University School of Medicine   (South Korea)

^c Daegu Fatima Hospital   (South Korea)

^d Chosun University College of Medicine   (South Korea)

Author keywords

aspergillosis; fungal infection; hyponatremia; therapeutic drug monitoring; voriconazole

Indexed keywords

CREATININE; CYCLOSPORIN; CYTOCHROME P450 2C19; METHYLPREDNISOLONE; POTASSIUM; PREDNISOLONE; SODIUM; STEROID; TETRACOSACTIDE; THYMOCYTE ANTIBODY; VORICONAZOLE;

ADULT; AGED; APLASTIC ANEMIA; ARTHRITIS; ARTICLE; CASE REPORT; CONFUSION; CREATININE BLOOD LEVEL; DROWSINESS; DRUG DOSE REDUCTION; DRUG WITHDRAWAL; FEMALE; HUMAN; HYPONATREMIA; LOADING DRUG DOSE; LUNG ASPERGILLOSIS; MAINTENANCE THERAPY; MALE; POTASSIUM BLOOD LEVEL; SERUM OSMOLALITY; SODIUM BLOOD LEVEL; SODIUM URINE LEVEL; SYSTEMIC SCLEROSIS; URINE OSMOLALITY;

AGED; ANTIFUNGAL AGENTS; ASPERGILLOSIS; DRUG MONITORING; FEMALE; HUMANS; HYPONATREMIA; MALE; MIDDLE AGED; PYRIMIDINES; SERUM; TRIAZOLES;

EID: 83755164269     PISSN: 13693786     EISSN: 14602709     Source Type: Journal    
DOI: 10.3109/13693786.2011.587210     Document Type: Article

References (11)

1. Walsh TJ, Anaissie EJ, Denning DW, et al. Treatment of aspergillosis: Clinical practice guidelines of the Infectious Diseases Society of America. Clin Infect Dis 2008; 46: 327-360. (Pubitemid 351265310)
2. Boyd AE, Modi S, Howard SJ, e t al. Adverse reactions to voriconazole. Clin Infect Dis 2004; 39: 1241-1244. (Pubitemid 40169325)
3. Isobe K, Muraoka S, Sugino K, e t al. Case of pulmonary aspergillosis associated with inappropriate antidiuretic hormone syndrome caused by voriconazole therapy. Nihon Kokyuki Gakkai Zasshi 2007; 45: 489-493.
4. Teranishi J, Nagatoya K, Kakita T, e t al. Voriconazole-associated salt-losing nephropathy. Clin Exp Nephrol 2010; 14: 377-380.
5. Naranjo CA, Busto U, Sellers EM, e t al. A method for estimating the probability of adverse drug reactions. Clin. Pharmacol. Ther. 1981; 30: 239-245. (Pubitemid 12149145)
6. Jeong S, Nguyen PD, Desta Z. Comprehensive in vitro analysis of voriconazole inhibition of eight cytochrome P450 (CYP) enzymes: major effect on CYPs 2B6, 2C9, 2C19, and 3A. Antimicrob AgentsChemother 2009; 53: 541-551.
7. Ellison DH, Berl T. Clinical practice. The syndrome of inappropriate antidiuresis.nEngl J Med 2007; 356: 2064-2072. (Pubitemid 46789896)
8. Lewis RE. What is the therapeutic range for voriconazole? Clin Infect Dis 2008; 46: 212-214.
9. Bruggemann RJ, Donnelly JP, Aarnoutse RE, e t al. Therapeutic drug monitoring of voriconazole. Ther Drug Monit 2008; 30: 403-411.
10. Theuretzbacher U, Ihle F, Derendorf H. Pharmacokinetic/ pharmacodynamic profi le of voriconazole. Clin Pharmacokinet 2006; 45: 649-663.
11. Smith J, Andes D. Therapeutic drug monitoring of antifungals: pharmacokinetic and pharmacodynamic considerations. Ther Drug Monit 2008; 30: 167-172. (Pubitemid 351521643)